Study of Combination Therapy With Dimebon and Donepezil (Aricept) in Patients With Alzheimer's Disease

This study has been terminated.

(The study was halted after a Phase 3 study of dimebon failed to show efficacy.)

Sponsor:

Medivation, Inc.

ClinicalTrials.gov Identifier:

NCT00704782

First Posted: June 25, 2008

Last Update Posted: December 10, 2015

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:

50 Years and older (Adult, Senior)

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Alzheimer's disease

On donepezil (Aricept)

Caregiver who cares for the patient at least 5 days per week

Exclusion Criteria:

Unstable medical illnesses or significant hepatic or renal disease

Other primary psychiatric or neurological disorders

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00704782